DGAP-News: Medios AG / Key word(s): 9-month figures
Medios AG continues its dynamic growth in the first nine months 2017
Berlin, 13 November 2017 - Medios AG, one of the leading Specialty Pharma companies in Germany, has continued its dynamic growth in the first nine months 2017 and confirms the sales forecast as well as the earnings forecast for the full year. In the period from January to September, Medios generated consolidated sales of EUR 187.3 million (IFRS), already surpassing the consolidated sales of full year 2016 significantly (prior year EUR 160.4 million, pro-forma IFRS). For the full year 2017, the Management Board still expects consolidated sales of around EUR 230 million. The forecast for consolidated earnings before taxes (EBT) in the amount of EUR 7.0 million up to EUR 7.5 million before special effects remains unchanged. In this context, burdens through growth investments and the consequences of the abolition of cytostatic drug tenderings through the German Act on Strengthening Pharmaceutical Supply in Statutory Health Insurance, which are not yet foreseeable, have already been considered. In contrast, the non-cash special effect through the stock option programme, which was implemented on the basis of the resolution of the Annual General Meeting 2017 in order to incentivise the management team, is not considered. The special effect will cause an extraordinary expense amounting to around EUR 1.1 million in the full year 2017.
Manfred Schneider, CEO of Medios AG: "The sustained high demand for individualised medicine in the first nine months 2017 makes us confident that we will increase our sales by some 44 percent to around 230 million euro as planned. Thereby, we take a further step towards our aim to become the leading provider of Specialty Pharma solutions in Germany."
In the first nine months 2017, Medios focused on the implementation of the growth strategy. The most important measures included the establishment of the Medios Digital GmbH subsidiary, the purchase of a property in Berlin-Charlottenburg, the successful placement of new shares with institutional investors within a cash capital increase and the purchase of additional clean room capacities in order to accelerate the expansion of the manufacturing capacities for individualised medicine.
About Medios AG
Medios AG is Germany's first listed Specialty Pharma company. The share (WKN: A1MMCC, ISIN: DE000A1MMCC8) is listed in the Regulated Market of the Frankfurt Stock Exchange (General Standard) and Hamburg-Hannover Stock Exchange.
|Phone:||+49 30 232 566 - 800|
|Fax:||030 / 8321 8377|
|Listed:||Regulated Market in Frankfurt (General Standard), Hamburg; Regulated Unofficial Market in Dusseldorf|
|End of News||DGAP News Service|